Site-specific Hypermethylation of RUNX3 Predicts Poor Prognosis in Gastric Cancer

Background and AimsMethylation status of RUNX3 remains largely unknown in gastric cancer (GC). The aim of this study was to prognostically evaluate the methylation level of CpG sites within RUNX3 promoter region in GC.MethodsUsing pyrosequencing, we quantitatively explored the methylation status of 8 CpG sites within RUNX3 promoter region for 76 gastric cancer and 24 normal gastric tissues. We then analyzed the association between methylation level of each CpG site and clinicopathological characteristics and outcomes in the cohort.ResultsMethylation of RUNX3 promoter was significantly higher in GC than normal subjects. Overall methylation level was closely associated with tumor invasion and TNM stage. Positive associations were found between hypermethylation of the following concerned sites and variables: site −1392, −1397, −1403, −1415 and tumor invasion, as well as TNM stage; site −1392 and lymph node metastasis along with number of lymph node metastases; site −1415 and cancer recurrence; site −1403, −1415 and cancer-related deaths. In multivariate analysis, tumor invasion was correlated with sites −1392 and −1397. Lymph node metastasis was associated with site −1392. Most importantly, methylation of site −1415 was associated with poor survival by using Cox survival regression.ConclusionAnalysis of RUNX3 gene promoter by quantitative pyrosequencing suggested methylation status of RUNX3 is different in normal and tumor tissues. RUNX3 methylation level is associated with GC, especially the methylation at site −1415 contributes to the poor prognosis in GC. Thus, RUNX3 methylation may serve as a valuable diagnostic and prognostic biomarker in GC.